Multifunctional nanozymes for sonodynamic-enhanced immune checkpoint blockade therapy by inactivating PI3K/AKT signal pathway.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39893781.
- Also identified by DOI 10.1016/j.biomaterials.2025.123125.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Insufficient activation efficacy and tumor immunosuppressive microenvironments hinder the infiltration of cytotoxic T lymphocytes (CTLs) for effective immunotherapy. Herein, the pH-selective multienzyme-mimetic nanozymes have been developed based on Pd-hemoporfin (Pd<sup>0</sup>/Pd<sup>2+</sup>‒H) nanoagents for tumor sono-immunotherapy via the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway inactivation. The Pd<sup>0</sup>/Pd<sup>2+</sup>‒H is capable of catalase-mimetic, peroxidase-mimetic, and sonodynamic effects, creating an O<sub>2</sub>-rich environment and elevating the reactive oxygen species (ROS) levels. The elevated ROS levels down-regulate the expression of PI3K and p-AKT on both gene and protein levels, leading to PI3K/AKT pathway inactivation. Subsequently, the augmented immunogenic cell death effectively recruits dendritic cells, presents tumor-associated antigens, and activates antitumor T-cell immunity. As a result, the combination of Pd<sup>0</sup>/Pd<sup>2+</sup>‒H and anti-programmed cell death protein ligand 1 results in growth restraints of primary and precaution of tumor metastases. This work offers insights into developing multienzyme-mimetic nanozymes in signaling pathway regulation and antitumor strategy.
Medical subject headings
- Signal Transduction
- Immune Checkpoint Inhibitors
- Proto-Oncogene Proteins c-akt
- Phosphatidylinositol 3-Kinases